| Source: HalifaxProj (inhibit) |
| Type: |
| mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status. mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation. mTor Inhibitors: -rapamycin (Sirolimus): classic natural product mTOR inhibitor -Curcumin -Resveratrol -Epigallocatechin Gallate (EGCG) -Honokiol |
| Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms. The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42). |
| 4688- | HNK, | Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling |
| - | vitro+vivo, | RCC, | A498 |
| 109- | SIL, | Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma |
| - | vitro+vivo, | RCC, | 769-P | - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | RCC, | OS-RC-2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:24 Cells:% prod#:% Target#:209 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid